- Home
- SST vs EVAX Comparison
SST vs EVAX Comparison
Compare SST & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | EVAX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | Denmark |
| Employees | 300 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 27.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SST | EVAX |
|---|---|---|
| Price | $1.77 | $3.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $11.67 |
| AVG Volume (30 Days) | 19.3K | ★ 29.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $1.20 |
| 52 Week High | $11.30 | $12.15 |
Technical Indicators
Market Signals| Indicator | SST | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 16.84 | 57.70 |
| Support Level | $0.34 | $2.45 |
| Resistance Level | $4.61 | $5.48 |
| Average True Range (ATR) | 0.32 | 0.34 |
| MACD | -0.12 | 0.11 |
| Stochastic Oscillator | 5.88 | 62.94 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.